Black Friday saleUp to 70% OFF
Mirum Pharmaceuticals, Inc.Mirum Pharmaceuticals, Inc.Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

MIRM chart


Full chart

MIRM upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.15 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.07 USD
Net income (FY)
‪−163.41 M‬ USD
Revenue (FY)
‪186.37 M‬ USD
Shares float
‪38.21 M‬
Beta (1Y)
0.41

Employees


Employees (FY)
264
Change (1Y)
+68 +34.69%
Revenue / Employee (1Y)
‪705.96 K‬ USD
Net income / Employee (1Y)
‪−619.00 K‬ USD

About Mirum Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Christopher Peetz
Headquarters
Foster City
Website
mirumpharma.com
Founded
2018
FIGI
BBG00MH7T2M7
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

MIRM news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

MIRM highest yielding bonds


MIRM5806400
Mirum Pharmaceuticals, Inc. 4.0% 01-MAY-2029
Yield to maturity
−3.93%
Maturity date
May 1, 2029

Explore more bonds 

Frequently Asked Questions


The current price of MIRM is 44.73 USD — it has increased by 2.87% in the past 24 hours. Watch Mirum Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Mirum Pharmaceuticals, Inc. stocks are traded under the ticker MIRM.
MIRM stock has fallen by −3.62% compared to the previous week, the month change is a 13.24% rise, over the last year Mirum Pharmaceuticals, Inc. has showed a 40.40% increase.
We've gathered analysts' opinions on Mirum Pharmaceuticals, Inc. future price: according to them, MIRM price has a max estimate of 73.00 USD and a min estimate of 50.00 USD. Watch MIRM chart and read a more detailed Mirum Pharmaceuticals, Inc. stock forecast: see what analysts think of Mirum Pharmaceuticals, Inc. and suggest that you do with its stocks.
MIRM reached its all-time high on Nov 14, 2024 with the price of 48.89 USD, and its all-time low was 6.51 USD and was reached on Nov 20, 2019. View more price dynamics on MIRM chart.
See other stocks reaching their highest and lowest prices.
MIRM stock is 4.03% volatile and has beta coefficient of 0.41. Track Mirum Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Mirum Pharmaceuticals, Inc. there?
Today Mirum Pharmaceuticals, Inc. has the market capitalization of ‪2.15 B‬, it has decreased by −2.29% over the last week.
Yes, you can track Mirum Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Mirum Pharmaceuticals, Inc. is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
MIRM earnings for the last quarter are −0.30 USD per share, whereas the estimation was −0.45 USD resulting in a 33.25% surprise. The estimated earnings for the next quarter are −0.30 USD per share. See more details about Mirum Pharmaceuticals, Inc. earnings.
Mirum Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪90.38 M‬ USD, despite the estimated figure of ‪81.99 M‬ USD. In the next quarter, revenue is expected to reach ‪95.40 M‬ USD.
MIRM net income for the last quarter is ‪−14.23 M‬ USD, while the quarter before that showed ‪−24.64 M‬ USD of net income which accounts for 42.22% change. Track more Mirum Pharmaceuticals, Inc. financial stats to get the full picture.
No, MIRM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 264.00 employees. See our rating of the largest employees — is Mirum Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Mirum Pharmaceuticals, Inc. EBITDA is ‪−70.49 M‬ USD, and current EBITDA margin is −52.76%. See more stats in Mirum Pharmaceuticals, Inc. financial statements.
Like other stocks, MIRM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Mirum Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Mirum Pharmaceuticals, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Mirum Pharmaceuticals, Inc. stock shows the strong buy signal. See more of Mirum Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.